ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO890

Renal Outcome With Empagliflozin in Non-Diabetic CKD Patients: A Randomized Control Trial

Session Information

Category: CKD (Non-Dialysis)

  • 2202 CKD (Non-Dialysis): Clinical‚ Outcomes‚ and Trials


  • Nisar, Zara, Khyber Medical University, Peshawar, Pakistan
  • Sajjad, Hassan, Rehman Medical Institute, Peshawar, Pakistan
  • Kumar, Akash, Rehman Medical Institute, Peshawar, Pakistan
  • Afaq, Saima, Khyber Medical University, Peshawar, Pakistan
  • Anwar, Nisar, Rehman Medical Institute, Peshawar, Pakistan

As CKD is a rapidly growing disease, it needs rigorous treatment to control its progression.New treatment options for diabetic and non-diabetic CKD are needed


This was a single centre trial(Trial registration: ACTRN12622000265774p). Study schema is in the figure.
STUDY SETTING: Khyber Teaching Hospital.
SAMPLE SIZE AND POWER: 70 per arm in 1:1 ratio.
Statistical Analysis: Microsoft Excel was used to collect the raw data. SAS was used to manage the data and conduct the statistical analyses. This data was summarized to calculate the mean, median, interquartile range (IQR) and standard deviation for continuous variables. Categorical variables were summarized by means of counts and percentages per category.
Pairwise correlation coefficient was calculated among the variables to explore between-participant variation. We used multivariate analysis of covariance (MANCOVA) main effect model which is the most efficient approach with smallest variance estimator.


The mean age of the partcipants was 57.9 ±4.51, with 51% being male. The treatment’s impact on the five variables of TotalCholesterol60, TotalCholesterol90, LDL60, LDL90, and Proteinuria60; were found to be statistically significant. On average, the treatment decreased a patient's total cholesterol by 20 units after 60 days. It decreased a patient's total cholesterol by 70 units after 90 days. LDL is decreased by 30 units after 60 days, and by 37 units after 90 days. As for proteinuria, the treatment decreased it by 350 units after 60 days. Up to the 60 days, UTI events for the treatment group were more than those for the control group. At the 90-day stage, males had more UTI events in the treatment group than their control counterparts whereas females in the treatment group had fewer events than their control counterparts


We conclude that Empagliflozin along with standard therapy has beneficial effect for the symptoms of the patients. Follow-up duration should be increased to see its effect on e-GFR.


  • Private Foundation Support